Stability Indicating HPTLC Method for Estimation of Dabigatran Etexilate Mesylate in its Pharmaceutical Dosage Form
 
More details
Hide details
1
Maliba Pharmacy College, INDIA
CORRESPONDING AUTHOR
Pintu B. Prajapati   

Maliba Pharmacy College, Bardoli-Mahuva Road, Bardoli, Gujarat, India
Online publication date: 2016-12-09
Publication date: 2016-12-09
 
Eurasian J Anal Chem 2017;12(2):75–86
KEYWORDS
TOPICS
ABSTRACT
Dabigatran etexilate mesylate is an anticoagulant drug. Dabigatran demonstrated its efficacy for prophylaxis and treatment of thromboembolic event during orthopaedic surgery and curative treatment of hypercoagulability in atrial fibrillation. The present study deals with the development and validation of a stability-indicating high performance thin-layer chromatography (HPTLC) method for the estimation of Dabigatran etexilate mesylate using TLC plates precoated with silica gel 60 F254 as stationary phase and toluene: ethyl acetate: methanol: formic acid (3:4:3:0.2, v/v/v/v) as the mobile phase. The drug was subjected to stress conditions such as hydrolysis, oxidation, photolysis, neutral and dry heat. Degradation products produced as a result of the stress conditions did not interfere with the detection of DEM, therefore the proposed method can be considered stability-indicating. DEM showed degradation under hydrolytic, oxidative, photolytic and dry heat conditions. DEM (Rf 0.47 ± 0.02) and its degradation products were well resolved. The wavelength selected for quantitation was 314 nm. The method was linear in the concentration range 50-250 ng/spot with a correlation coefficient of 0.9955. The %RSD for repeatability of peak area measurement was found to be 0.62 and %RSD for repeatability of sample application was found to be 0.75. The % RSD of intraday and interday precisions were 0.91- 1.5 and 1.21- 1.7 respectively. The accuracy (recovery) was found to be in the range of 99.45-100.37 %. The developed method was applied for assay of marketed formulations and the results were found to be good agreement with labelled claim of formulations.
 
REFERENCES (16)
1.
Jewell, C., & Shiromani, P. (2010). Center for Drug Evaluation and Research (CDER). CMC Review.
 
2.
European Medicines Agency (2008). Evaluation of medicines for human use (EMEA). CHMP Assessment report Pradaxa.
 
3.
ICH Guidelines Q1A (R2). (2003). Stability Testing of New Drug Substances and Products. ICH, Geneva, Switzerland.
 
4.
Shethi, P. D. (1996). High Performance Thin Layer Chromatography-Quantitative analysis of pharmaceutical formulations, 1st ed., CBS Publishers, New Delhi, pp. 1-68.
 
5.
Prajapati, A., & Kumar, S. (2014). Spectrophotometric method for estimation of dabigatran etexilate in bulk and its pharmaceutical dosage form. An international journal of Pharmaceutical Sciences, 5(2), 31-39.
 
6.
Damle, M. C., & Bagwe, R. A. (2014). Development and validation of stability-indicating RP-HPLC method for estimation of dabigatran etexilate. Journal of Advanced Scientific Research. 5(3), 39-44.
 
7.
Reddy, S., & Rao, V. B. (2014). A stability indicating RP-HPLC method for estimation of dabigatran in pure and pharmaceutical dosage forms. South pacific Journal of Pharma and Bio Science, 2(1), 80-92.
 
8.
Shelke, P. G., & Chandewar, A. V. (2014). Validated stability-indicating high performance liquid chromatographic assay method for the determination of Dabigatran Etexilate Mesylate. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 5(2), 1637-1644.
 
9.
Geetharam, Y., Mallesh, M., Gupta, R., & Sridhar, B. (2014). Validated stability-indicating liquid chromatographic method for the determination of dabigatran etexilate (thrombin inhibitor). in capsules. Indo American Journal of Pharmaceutical Research,, 4(4), 2141-2150.
 
10.
Bernardi, R. M., Froehlich, P. E., & Bergold, A. M. (2013). Development and validation of a stability-indicating liquid chromatography method for the determination of dabigatran etexilate in capsules. Journal of AOAC International, 96(1), 37-41.
 
11.
Xavier, D. B., Julie, M., Silvy, L., Patrick, M., & Thierry, B. (2012). UPLC MS/MS assay for routine quantification of dabigatran – A direct thrombin inhibitor – In human plasma. Journal of Pharmaceutical and Biomedical Analysis, 58, 152-156.
 
12.
Zhe-Yi, H., Robert, B. P., Vanessa, L. H., & Laizure, C. S. (2013). Conventional liquid chromatography/ triple quadruple mass spectroscopy based metabalite identification and semi quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolite. Anal Bioanal Chem. 405(5), 1695–1704.
 
13.
Marie, K., Kevin, B., Lison, F., Nadine, T., Jean-Sebastien, H., Christian, F., & Noël, Z. (2014). Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography–tande mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 100, 230–235.
 
14.
Li, J., Fang, J., Li, W., Tang, Y., Xu, Y., Mao, S., & Fan, G. (2014). Development and validation of a liquid. Chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate, intermediate metabolite and dabigatran in 50µL rat plasma and its application to pharmacokinetic study. Journal of Chromatography B, 1-40.
 
15.
Patel, B., Ram, P., Khatri, T., & Dave, P. (2014). Study of Anticoagulant Dabigatran by Analytical Instrumentation. International Letters of Chemistry, Physics and Astronomy, 11(3), 233-242.
 
16.
ICH Harmonised Tripartite Guideline. (2009). Validation of Analytical procedures, Text and Methodology Q2 (R1). International conference on Harmonisation. Geneva, Switzerland.
 
eISSN:1306-3057